Genetically engineered poly-gamma-glutamate producer from Bacillus subtilis ISW1214

Bioscience, Biotechnology, and Biochemistry
Makoto AshiuchiHaruo Misono


The pgsBCA-gene disruptant from Bacillus subtilis ISW1214, i.e., MA41, does not produce poly-gamma-glutamate (PGA). We newly constructed an MA41 recombinant bearing the plasmid-borne PGA synthetic system, in which PGA production was strictly controlled by the use of xylose. Unlike the parent strain, ISW1214, the genetically engineered strain produced abundant PGA in both L-glutamate-rich and D-glutamate-rich media.


Mar 1, 1996·European Journal of Biochemistry·H Kleinkauf, H Von Döhren
Apr 1, 1996·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·S VaganayD Blanot
Oct 19, 2001·European Journal of Biochemistry·Makoto AshiuchiHaruo Misono
Dec 26, 2001·Journal of Bacteriology·Yuji UrushibataYasutaka Tahara
Jul 9, 2004·Applied and Environmental Microbiology·Makoto AshiuchiHaruo Misono


Dec 17, 2014·Microbial Cell Factories·Kiyotaka Y HaraAkihiko Kondo
Mar 8, 2011·Bioresource Technology·Ishwar Bajaj, Rekha Singhal
Aug 28, 2007·Biochemical and Biophysical Research Communications·Makoto AshiuchiHaruo Misono
Sep 3, 2010·Biotechnology and Bioengineering·Daisuke YamashiroMakoto Ashiuchi
Apr 14, 2016·BioMed Research International·Biaosheng LinMaochun Luo
Oct 8, 2014·Microbiology·Adetoro OgunleyeIza Radecka
Dec 8, 2017·International Journal of Molecular Sciences·Yi-Huang HsuehTzong-Yi Lee

Related Concepts

Natto Bacteria
Genetic Engineering
Molecular Stereochemistry
Glutamic Acid, (D)-Isomer

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.